DOCSLIB.ORG

Welcome to Drug Discovery 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

www.elrig.org Welcome to Drug Discovery 2019 As Scientific Program chairs it is our great pleasure to welcome you back to Liverpool for the 13th Annual ELRIG Drug Discovery event. Our organising committee and session chairs have been working hard since late 2018 and thanks to them we have again been able to assemble a world-class line up of scientific speakers. This year we have 8 thematic tracks over 2 days with over 50 invited speakers, over 100 posters and as always a sold out and vibrant exhibition hall. We encourage you to get to as much of the science as you possibly can and to take full advantage of the exhibitor’s expertise and knowledge to improve your own discovery sciences. The vendor presence at ELRIG ensures that these conferences are of minimal cost to attendees, so please show your appreciation by visiting the booths and asking as many probing and difficult questions of their technology as possible. With these questions they are better equipped to supply us with the tools of the future to make the next set of discoveries. We are sure there will be something for everyone at this year’s Drug Discovery. We have tried to reflect hot topics and trends in the Drug Discovery field in this year’s tracks and we invite our speakers to take a look back at the future. We aim to ponder on both how we have arrived at this exciting era of drug discovery and to look ahead to what the future may hold. We are also delighted to welcome sessions hosted by the British Pharmacological Society and Cancer Research UK, focusing on ion channels and oncology drug discovery respectively. We would again like to thank Rhona Bennett, Clare Cockerham, Sanj Kumar and Tara Shanks in the ELRIG office for their fantastic contribution in shepherding ourselves and the Program Chairs through the organising process. Without their help, together with the all the other volunteers, this meeting would not be possible. Finally, without you, the meeting delegate, we have nothing too. We thank you in advance for your participation and look forward to connecting with you over the next couple of days. As always, we welcome your feedback on how we can further improve the agenda to ensure the growth and success of ELRIG Drug Discovery for the future. Have fun in Liverpool and enjoy the opportunity to discuss emerging Science within a vibrant and collegiate environment! Chun-wa Chung Tim Hammonds Katy Kettleborough (GlaxoSmithKline) (Cancer Research UK) (LifeArc) A Message from the Chair of ELRIG, Steve Rees On behalf of ELRIG I would like to welcome you to the 13th Drug Discovery meeting and our return to Liverpool. During 2019 ELRIG has held four outstanding scientific events attracting over 1300 delegates. With the 1400 scientists expected to attend Drug Discovery this will be a record year for ELRIG in terms of meeting delegates and vendor exhibitions. Alongside this our networking events programme is now established in major science centres across the UK, and the Early Career Professional Work group has run a series of events to engage with, and support, junior scientists as they embark on their careers. We have an exciting scientific program in place for 2020. Following the success of our first meeting on CRISPR in Drug Discovery we will be revisiting this topic in March in Cambridge. For the first time our Research and Innovation meeting will be held in Oxford in April, we will be returning to Gothenburg for a Cell Therapy meeting in June and Stevenage for our Flow Cytometry and Imaging meeting in the autumn. Alongside this we look forward to returning to the ExCeL in London for Drug Discovery 2020 in October. The success of ELRIG is dependent upon the many volunteers who give their time freely to create our meetings and other events. Volunteers are supported by an outstanding ELRIG office team; Sanj Kumar, Tara Shanks, Rhona Bennett and Clare Cockerham. I would like to thank everyone involved in ELRIG for the work that they do for this organisation. Looking ahead to the next two days we have an outstanding scientific program to look forward too, together with our largest ever vendor exhibition. I would like to thank the science committee, session chairs, speakers, exhibitors and of course you for attending this meeting. As I have said before my challenge to all delegates is to learn something new, meet someone new and see something new to advance your research. Have a great few days! #ELRIG Drug Discovery 2019 Session Chairs Tuesday 5th November 2019 Wednesday 6th November 2019 Cellular Models of Disease Molecular and Cellular Imaging Paul Andrews Robert Vries Michael Hennig (University of Dundee) (Hubrecht Organoid (leadXpro) Technology) Chemical biology – re-defining target Biomarkers Strategies tractability and therapeutic class in Drug Discovery Marcus Bantscheff Satpal Virdee Sally Price Ian Pike (Cellzome) (University of Dundee) (Medicines Discovery (Ian Pike Consulting) Catapult) Big Data and Artificial Intelligence Hit Finding Strategies Ola Engkvist Hugo Ceulemans Philip Gribbon Rosemary Burke (AstraZeneca) (Jansen pharmaceuticals) (Fraunhofer IME (Institute of Cancer Screening Port) Research) Targeting Ion Channels for Drug Discovery Oncology Drug Discovery hosted by the British Pharmacological Society hosted by Cancer Research UK Sarah Nickolls David Kendall Graeme Walker Heather McKinnon (GlaxoSmithKline) (Pharmnovo) (Cancer Research UK (The Beatson Institute Manchester Institute) for Cancer Research) #ELRIG Plenary Keynote Speakers Dr. Mene Pangalos (AstraZeneca) “Turning science into medicine: Hot trends and the business landscape” Tuesday 5th November 2019: 09:15: Room 3A The future treatment for many of today’s diseases lies in discovering new biology, understanding and challenging scientific hypotheses, to develop novel therapies. Improving R&D productivity is critical to the success of drug discovery, with failure rates from pre-clinical development to launch often in excess of 90 percent. The advent of data science and artificial intelligence, coupled with ever more sophisticated platform technologies, such as dynamic multi-omics brings with it an expanding list of pathways and targets to pursue - and with-it new drug discovery challenges. Exploring novel drug modalities which complement existing strengths in small molecule and biologic platforms has the potential to open new therapeutic options, and to help us prosecute drug targets traditionally viewed as intractable. Over the past few years we have made significant progress across seven additional drug discovery platforms, complementing existing capabilities in chemistry and protein engineering. These include modified mRNA therapies, antisense oligonucleotides (ASOs), oligonucleotide conjugates, bicyclic peptides, proteolysis targeting chimeras (PROTACs), anticalins and CRISPR. By combining new technologies, focusing on medical understanding, challenging scientific hypotheses and driving strategic private and academic partnerships, we are making real progress in our ability to define and prosecute novel treatment approaches for a variety of difficult to treat diseases. Dr. Fiona Marshall (MSD) “Tackling diseases of ageing – the application of new approaches in drug discovery and development.” Wednesday 6th November 2019: 09:10: Room 3A Populations around the world are increasing in age and this is leading to a rise in the incidence of diseases associated with ageing. In particular, the number of people with neurodegenerative disease is placing a burden on families and healthcare systems. Despite many recent failures in developing treatments for dementia there is much hope for the future. New insights from genetics is increasing our understanding of key mechanisms underlying ageing and related diseases. Multiple therapeutic modalities are being evaluated to modulate genes and proteins involved in disease in human cell models. Finally, novel biomarkers and imaging techniques can be utilized to diagnose and stratify patients and to track the progression of disease. In combination these advances are set to alter future treatments for diseases of ageing. Industry Insider Presentation Dr. Melanie Lee (LifeArc) “Nurturing effective translation” Wednesday 6th November 2019: 10:20: Room 3A LifeArc has a 25-year legacy of collaborating with scientists, academics and industry on diagnostics and therapies, enhancing and protecting innovation, and advancing promising research. We have been enormously successful in these endeavours. But the world we deliver products into doesn’t stand still. Healthcare, science and technology are ever-changing, and this applies to translation as well. In the future, pharmaceutical companies will still need well prepared, validated therapeutic opportunities. But to be differentiated, the products will need to carry more information than they have in the past. Diagnostics will be able to identify much earlier those patients at likelihood of developing a condition. Advances in data analytics and genomic information will enable greater targeting of medicines to a sub-set of patients. How do we nurture effective translation as the world of digital informatics rapidly evolves? #ELRIG Information for Participants Registration Awards at Drug Discovery 2019 Registration will take place on the ground floor. Please ELRIG Early Career Professional Impact Award collect your name badge and event programme from the registration desk. For security reasons it is essential sponsored by to wear your badge at all times whilst attending Drug Discovery 2019. Attendees will not
Recommended publications
  • Directory of Companies A

    Directory of Companies A

    65 Directory of Companies A An alphabetical list of pharmaceutical companies, as well as manufacturers and suppliers of products and services for Medicinal Chemistry in Europe 3B PHARMACEUTICALS GMBH Magnusstraße 11 12489 BERLIN DE 3M BELGIUM Canadastraat 11, Haven 1005 2070 ZWIJNDRECHT BE 3V-LSI Rubicondreef 18 3561 JC UTRECHT NL of Companies 4SC AG Am Klopferspitz 19a 82152 MARTINSRIED DE A & D INSTRUMENTS LTD Abingdon Science Park OX14 3YX ABINGDON GB ABBVIE DEUTSCHLAND GMBH & CO. KG Knollstrasse 67061 LUDWIGSHAFEN DE Directory ABCR GMBH Im Schlehert 10 76187 Karlsruhe, GERMANY Contact person: Dr. Ute Kiso Tel: +49 721 95061-0 - [email protected] www.abcr.de Gute Chemie. Welcome to abcr. With abcr, you have access to over 260,000 products from the organic, organometallic and inorganic specialty chemicals area. These can be conveniently ordered via our webshop www.abcr.de > Catalogue & Bulk business from grams to tons > Scale up & Commercial manufacturing from our own facility > Sourcing & Logistic management worldwide > Feasibility studies & Synthesis at the laboratory scale > Custom syntheses & Contract Manufacturing ABSORPTION SYSTEMS 440 Creamery Way Suite 300 PA 19341 EXTON US AC IMMUNE SA EPFL Innovation Park Building B 1015 LAUSANNE FR ACCELA CHEMBIO 9823 Pacific Heights Blvd # F 92121 SAN DIEGO US ACRAF S.P.A. Piazzale della Stazione 40 S. PALOMBA - POMEZIA IT ACROS ORGANICS Janssen Pharmaceuticalaan 3a 2440 GEEL BE ACS Journal of Medicinal Chemistry & ACS Medicinal Chemistry Letters Contact person: Janice E. Silverman, Acquisitions Editor Tel: +1 202-577-5975 [email protected] Journal of Medicinal Chemistry – pubs.acs.org/jmc ACS Medicinal Chemistry Letters – pubs.acs.org/acsmedchemlett In 2017 Journal of Medicinal Chemistry is celebrating 60 years of publishing the field’s best peer-reviewed research.
  • The Scientific Organizing Committee Gratefully Acknowledges the Pharmaceutical and Biotechnology Industry for Their Generous Support of WCBP 2019

    The Scientific Organizing Committee Gratefully Acknowledges the Pharmaceutical and Biotechnology Industry for Their Generous Support of WCBP 2019

    The Scientific Organizing Committee gratefully acknowledges the pharmaceutical and biotechnology industry for their generous support of WCBP 2019: Strategic Diamond Program Partners F. Hoffmann-La Roche Ltd. Genentech, a Member of the Roche Group Strategic Platinum Program Partners Amgen Inc. Biogen MedImmune, A member of the AstraZeneca Group Strategic Gold Program Partners Eli Lilly and Company Merck & Co., Inc. Novo Nordisk A/S Pfizer, Inc. Strategic Silver Program Partner Sanofi 1 Gold Program Partner Bill and Melinda Gates Foundation Silver Program Partners BioMarin Pharmaceutical Inc. Bristol-Myers Squibb Company GlaxoSmithKline Jazz Pharmaceuticals Bronze Program Partner Seattle Genetics, Inc. Friend of CASSS Janssen R&D, LLC 2 The Scientific Organizing Committee gratefully acknowledges the Program Partners and Exhibitors for their generous support of WCBP 2019: Diamond Program Partners Agilent Technologies Catalent Pharma Solutions Eurofins Pharma Discovery Services ProteinSimple, a Bio-Techne brand Thermo Fisher Scientific Waters Corporation Platinum Program Partners BioAnalytix SCIEX Bronze Program Partner Bruker Corporation 3 The Scientific Organizing Committee gratefully acknowledges the Exhibitors for their generous support of WCBP 2019: Exhibitor Partners 908 Devices Inc. NanoImaging Services Agilent Technologies New England Biolabs Associates of Cape Cod, Inc. Postnova Analytics Inc. BioAnalytix Inc. Pressure BioSciences Inc. Bruker Corporation Protein Metrics, Inc. Catalent Pharma Solutions ProteinSimple, a Bio-Techne brand Charles River Laboratories ProZyme, A part of Agilent Covance, Inc. RedShift BioAnalytics, Inc. Cygnus Technologies Rockland Immunochemicals, Inc. Envigo SCIEX Eurofins BioPharma Product Testing SGS Life Science Services Eurofins Pharma Discovery Services Shimadzu Scientific Instruments, Inc. FortéBio - Biologics by Molecular Devices Thermo Fisher Scientific GE Healthcare Life Sciences U.S.
  • Contents Page

    Contents Page

    Statement of Development Principles: Regeneration Of Boots Campus, Beeston, Nottingham June 2007 STATEMENT OF DEVELOPMENT PRINCIPLES: REGENERATION OF BOOTS CAMPUS, BEESTON, NOTTINGHAM (June 2007) Contents 1. Introduction................................................................................................2 PURPOSE.............................................................................................................................. 2 POLICY CONTEXT................................................................................................................ 3 2. Development Principles ............................................................................4 THE VISION........................................................................................................................... 4 KEY DEVELOPMENT PRINCIPLES ..................................................................................... 4 3. Key Issues ..................................................................................................7 HIGHWAYS AND ACCESS ................................................................................................... 7 BALANCE OF USES ............................................................................................................. 7 LISTED BUILDINGS .............................................................................................................. 9 ENVIRONMENT.....................................................................................................................9
  • Acacia Pharma Group

    Acacia Pharma Group

    This document comprises a prospectus (the “Prospectus”) relating to Acacia Pharma Group plc (the “Company” or “Acacia Pharma”) prepared in accordance with the prospectus regulation rules (the “Prospectus Regulation Rules”) of the UK Financial Conduct Authority (the “FCA”) made pursuant to section 73A of the Financial Services and Markets Act 2000, as amended (“FSMA”). This Prospectus has been approved by the FCA as the competent authority under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has been filed with and made available to the public in accordance with Rule 3.2 of the Prospectus Regulation Rules. The FCA only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Company or of the quality of the Ordinary Shares that are the subject of this Prospectus. Investors should make their own assessment as to the suitability of investing in the Ordinary Shares. In addition, this Prospectus has been drawn up as a simplified prospectus in accordance with Article 14 of the Prospectus Regulation. The Belgian Financial Services and Markets Authority (“Belgian FSMA”) was notified of the passporting of this Prospectus in accordance with Article 25 of the Prospectus Regulation. The Company and the Directors, whose names appear on page 39 of this document, accept responsibility for the information contained in this document. To the best of the knowledge of the Company and the Directors, the information contained in this document is in accordance with the facts and this document makes no omission likely to affect its import.
  • Gaseous “Nanoprobes” for Detecting Gas-Trapping Environments in Macroscopic Films of Vapor-Deposited Amorphous Ice DOI: 10.1063/1.5113505

    Gaseous “Nanoprobes” for Detecting Gas-Trapping Environments in Macroscopic Films of Vapor-Deposited Amorphous Ice DOI: 10.1063/1.5113505

    The University of Manchester Research Gaseous “nanoprobes” for detecting gas-trapping environments in macroscopic films of vapor-deposited amorphous ice DOI: 10.1063/1.5113505 Document Version Submitted manuscript Link to publication record in Manchester Research Explorer Citation for published version (APA): Talewar, S. K., Halukeerthi, S. O., Riedlaicher, R., Shephard, J., Clout, A., Rosu-Finsen, A., Williams, G. R., Langhoff, A., Johannsmann, D., & Salzmann, C. G. (2019). Gaseous “nanoprobes” for detecting gas-trapping environments in macroscopic films of vapor-deposited amorphous ice. The Journal of chemical physics, 151(13). https://doi.org/10.1063/1.5113505 Published in: The Journal of chemical physics Citing this paper Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version. General rights Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Takedown policy If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact [email protected] providing relevant details, so we can investigate your claim. Download date:30. Sep. 2021 Gaseous ‘nanoprobes’ for detecting gas-trapping environments in macroscopic films of vapor-deposited amorphous ice Sukhpreet K. Talewar,a Siriney O.
  • Acoustic Immunosensing of Exosomes Using a Quartz Crystal Microbalance with Dissipation Monitoring

    Acoustic Immunosensing of Exosomes Using a Quartz Crystal Microbalance with Dissipation Monitoring

    Acoustic immunosensing of exosomes using a quartz crystal microbalance with dissipation monitoring. Jugal Suthar,y,z Edward S. Parsons,{ Bart W. Hoogenboom,{,x Gareth R. Williams,y and Stefan Guldin∗,z yUCL School of Pharmacy, University College London, 29-39 Brunswick Square, Bloomsbury, London, WC1N 1AX, United Kingdom zDepartment of Chemical Engineering, University College London, Torrington Place, London, WC1E 7JE, United Kingdom {London Centre for Nanotechnology, 17-19 Gordon Street, London, WC1H 0AH xDepartment of Physics and Astronomy, University College London, Gower Street, London, WC1E 6BT E-mail: [email protected] Abstract Exosomes are endocytic lipid-membrane bound bodies with potential to be used as biomarkers in cancer and neurodegenerative disease. The limitations and scarcity of current exosome characterisation approaches has led to a growing demand for trans- lational techniques, capable of determining their molecular composition and physical properties in physiological fluids. Here, we investigate label-free immunosensing, using a quartz crystal microbalance with dissipation (QCM-D), to detect exosomes by ex- ploiting their surface protein profile. Exosomes expressing the transmembrane protein 1 CD63 were isolated by size-exclusion chromatography from cell culture media. QCM-D sensors functionalised with anti-CD63 antibodies formed a direct immunoassay towards CD63-positive exosomes, exhibiting a limit-of-detection of 1.7x108 and 1.1x108 exosome sized particles (ESPs)/ ml for frequency and dissipation response respectively, i.e., clin- ically relevant concentrations. Our proof-of-concept findings support the adoption of dual-mode acoustic analysis of exosomes, leveraging both frequency and dissipation monitoring for use in diagnostic assays. Introduction Extracellular vesicles (EVs) are heterogenous, biomolecular structures enclosed by a lipid bilayer.
  • Alderley Park the Future As a World-Class Life Science Facility Planning Application Summary Document

    Alderley Park the Future As a World-Class Life Science Facility Planning Application Summary Document

    DECEMBER 2015 ALDERLEY PARK THE FUTURE AS A WORLD-CLASS LIFE SCIENCE FACILITY PLANNING APPLICATION SUMMARY DOCUMENT Alderley Park is a world-class Life Science research and development (R&D) facility. The site currently houses around 190,000 sq m of premier scientific laboratory space, offices, restaurants, cafes, conferencing space and energy plant, set in 400 acres of parkland. As a centre for scientific research, it is one of the few facilities in the country with a comprehensive offering to support drug discovery and development. It was AstraZeneca’s global lead centre for cancer research, employing at its peak up to 10,000 people in highly skilled jobs. These facilities at Alderley Park are high-quality A planning application has been submitted to and high-tech, and require significant ongoing Cheshire East Council for future development investment to retain them. £550 million has been at Alderley Park. The planning application invested in Alderley Park since 1997 and further, has been allocated the reference number major investment is required to repurpose the site 15/5401M. from single to multi-occupier use, maintain the facilities and cover ongoing overheads. This summary document sets out the key elements of the proposals. ILLUSTRATIVE MASTERPLAN SIGNIFICANT INVESTMENT PROPOSED OVER THE NEXT 10 YEARS In March 2013, AstraZeneca announced The site was purchased by Bruntwood/MSP, its decision to relocate its R&D facilities to part of Alderley Park Ltd who now wish to Cambridge, leading to uncertainty over the secure the future of the site, retaining talent and future of Alderley Park and its role in the local jobs, by taking forward the Taskforce’s vision.
  • A Science and Innovation Audit Report for the Midlands Engine

    A Science and Innovation Audit Report for the Midlands Engine

    A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report 01 November 2016 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Contents Midlands Engine SIA – the headlines ....................................................................................1 1. Introduction to the Midlands Engine SIA...........................................................................4 2. SIA ‘hypotheses’ and ‘framework’ ...................................................................................10 3. Regional science and innovation assets and excellence..............................................19 4. Innovation strengths and our growth priorities..............................................................30 5. Market and technology drivers of change.......................................................................53 6. Innovation networks and behaviours ..............................................................................59 7. Next Steps – unlocking our productivity potential.........................................................67 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Midlands Engine SIA – the headlines 1. In Autumn 2015 the UK Government announced regional Science and Innovation Audits (SIAs) to catalyse
  • A Preclinical Evaluation of the Discriminative And

    A Preclinical Evaluation of the Discriminative And

    NP5101_proof ■ 12 June 2013 ■ 1/11 Neuropharmacology xxx (2013) 1e11 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm 1 56 2 A preclinical evaluation of the discriminative and reinforcing 57 3 58 4 properties of lisdexamfetamine in comparison to D-amfetamine, 59 5 fi 60 6 methylphenidate and moda nil 61 7 62 a,* a a a b 8 Q5 David J. Heal , Niki W. Buckley , Jane Gosden , Nigel Slater , Charles P. France , 63 9 David Hackett c 64 10 65 a 11 RenaSci Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK 66 b University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA 12 c Shire Pharmaceutical Development Ltd, Hampshire International Business Park, Chineham, Basingstoke RG24 8EP, Hampshire, UK 67 13 68 14 69 15 article info abstract 70 16 71 17 Article history: Lisdexamfetamine dimesylate, which consists of L-lysine covalently bound to D-amfetamine, is the first 72 18 Received 12 December 2012 prodrug for treating ADHD. Its metabolic conversion to yield D-amfetamine by rate-limited, enzymatic 73 19 Received in revised form hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other 74 3 April 2013 20 stimulants shown to be effective in managing ADHD include D-amfetamine, methylphenidate and 75 Accepted 13 May 2013 21 modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing 76 effects of these compounds were determined in rats using a 2-choice, D-amfetamine (0.5 mg/kg, i.p.)- 77 22 Keywords: cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration.
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry

    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry

    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.
  • Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting

    Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting

    Author Manuscript Published OnlineFirst on December 16, 2013; DOI: 10.1158/1535-7163.MCT-13-0420 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Fully Human Anti-Hedgehog Antibodies Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Authors: Neil R. Michaud1*, Youzhen Wang1, Kristen McEachern1, Jerold J. Jordan1, Anne Marie Mazzola1, Axel Hernandez1, Sanjoo Jalla2, Jon W. Chesebrough2, Mark J. Hynes3, Matthew Belmonte 1, Lidong Wang3, Jaspal S. Kang4#, Jelena Jovanović5, Naomi Laing1, David W. Jenkins1, Elaine Hurt2, Meina Liang6, Christopher Frantz7, Robert E. Hollingsworth2, Diane M. Simeone3, David C. Blakey8, and Vahe Bedian1* Authors’ affiliation: 1Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 2Oncology Research, MedImmune LLC, Gaithersburg, MD 3Translational Oncology Program, University of Michigan, Ann Arbor, MI; 4Amgen British Columbia, Burnaby, BC, Canada 5Lead Generation- Research, Medimmune LLC, Granta Park, Cambridge, UK 6Clinical Pharmacology and DMPK, MedImmune LLC, Hayward, CA 7Biologics Safety Assessment, MedImmune LLC, Mountain View, CA 8Oncology iMed, AstraZeneca, Alderley Park, Macclesfield. UK #Current address: Paul Kang, CSO, Innovative Targeting Solutions Inc., Burnaby BC, Canada *corresponding authors: Neil R. Michaud, Ph.D. Oncology iMED AstraZeneca-R&D Boston Waltham, MA 02451 e-mail: [email protected] Vahe Bedian Ph.D. Oncology iMED AstraZeneca-R&D Boston Waltham, MA 02451 phone:781-839-4613 e-mail: [email protected] Running title: Fully Human Anti-Hedgehog Antibodies Key Words: Hedgehog, Antibody, Xenograft, XenoMouse, cancer stem cells Grant Support: This work was funded by AstraZeneca PLC and MedImmune LLC. Disclosure of Potential Conflicts of Interest: There are no potential conflicts of interest.
  • United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group

    United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.